AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently amended) A compound of Formula (I) or a salt, or solvate, or physiologically functional derivative thereof:

$$Z$$
 X
 S
 N
 $R2$
 (I)

wherein:

- R1 is hydrogen or C₁₋₆alkyl;
- R2 is selected from the group consisting of C₁₋₆alkyl, C₁₋₄alkylNR⁷R⁸ (wherein R⁷ and R⁸ are independently H or C₁₋₄alkyl), aryl, CH(CH₂OH)aryl, arylC₁₋₆alkyl, aryloxyC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, wherein in each case the aryl, heteroaryl or heterocyclyl moiety is optionally substituted by one to five groups selected from the group consisting of halogen, NH₂, hydroxy, cyano, C₁₋₄alkyl, —OCH₂O-, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, aryloxy, C₁₋₄alkoxycarbonyl, —C₁₋₄hydroxyalkyl, C₁₋₄alkanoyl, C₁₋₄alkylsulfonyl, (CH₂)₀₋₄NHCOOC₁₋₄alkyl, and a group R₃R₄NSO₂ (wherein R₃ and R₄ are independently hydrogen or C₁₋₄alkyl) and a 5- or 6-membered heteroaryl group;
- or R1 and R2, together with the nitrogen atom to which they are joined, form a 5or 6-membered monocyclic heterocyclic ring or a 9- or 10-membered bicyclic heterocyclic ring wherein at least the ring which contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, and wherein the 5- or 6-membered monocyclic heterocyclic ring or the 9- or 10-membered bicyclic heterocyclic ring is optionally substituted by one to four groups selected from the group consisting of halogen, hydroxy, cyano, C₁₋₄alkanoyl, oxo, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, aryloxy and C₁₋₄alkoxycarbonyl;

X is indazolyl, pyrazolyl or a group

wherein

G is CH or N; and

Y is hydrogen or a group NR5R6 (wherein R5 and R6 are independently hydrogen, C_{1-6} alkyl), $(CH_2)_{0-6}$ phenyl (wherein the phenyl group is optionally substituted by halogen or OC_{1-4} alkyl);

and

- Z is hydrogen, halogen, cyano or a 5- or 6-membered heteroaryl.
- 2. (Original) A compound as claimed in claim 1, wherein R1 is hydrogen.
- 3. (Currently amended) A compound as claimed in claim 1-or claim-2, wherein R2 is aryiC₁₋₆alkyl optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkyl, halo C_{1-4} alkoxy, thiadiazolyl and a group $R_3R_4NSO_2$ wherein R_3 and R_4 are independently hydrogen or C_{1-4} alkyl.
- 4. (Currently amended) A compound as claimed in claim 1-or claim 2, wherein R1 and R2, together with the nitrogen atom to which they are joined, form a 6-membered monocyclic heterocyclic ring or a 10-membered bicyclic heterocyclic ring wherein at least the ring which each contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, wherein the 6-membered monocyclic heterocyclic ring or 10-membered bicyclic heterocyclic ring are both optionally substituted by one or two groups selected from oxo, C₁₋₄alkyl, phenyl and C₁₋₄alkoxycarbonyl.
- (Currently amended) A compound as claimed in <u>claim 1 any of claims</u>
 4, wherein X is indazolyl or pyrazolyl.
- 6. (Currently amended) A compound as claimed in <u>claim 1</u> any of claims 1-4, wherein X is 4-pyridinyl and Y is hydrogen.

7. (Currently amended) A compound as claimed in <u>claim 1</u> any of claims 1-4, wherein X is a group:

wherein Y_1 is a group NR5R6 whrein R5 and R6 are independently hydrogen or C_{1-6} alkyl.

- 8. (Currently amended) A compound as claimed in claim 1 any of claims 1-8 wherien Z is hydrogen or halogen.
- 9. (Currently amended) A compound as claimed in claim 1, wherein said compound is selected from the group consisting of which is:

N-(2-phenylethyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-methoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

5-(4-pyridinyl)-N-(2-pyridinylmethyl)-2-thiophenecarboxamide;

N-(1-naphthylmethyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-ethoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-bromobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-fluorobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-chlorobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-methylbenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-trifluoromethylbenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(2-trifluoromethoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-trifluoromethylbenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-fluorobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-chlorobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-bromobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide:

N-(3-iodobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-methylbenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-methoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-trifluoromethoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(3-phenoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;

N-(4-fluorobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide; N-(4-bromobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide; N-(4-iodobenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide; N-(4-trifluoromethylbenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide; N-(4-methylbenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide; N-(4-trifluoromethoxybenzyl)-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[4-(aminosulfonyl)benzyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[4-(methylsulfonyl)benzyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; 5-(4-pyridinyl)-N-(4-pyridinylmethyl)-2-thiophenecarboxamide; N-benzyl-N-methyl-5-(4-pyridinyl)-2-thiophenecarboxamide; 5-(4-pyridinyl)-N-[4-(1,2,3-thiadiazol-4-yl)benzyl]-2-thiophenecarboxamide; 5-(4-pyridinyl)-N-(3-pyridinylmethyl)-2-thiophenecarboxamide; N-[2-(2-methylphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-methylphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-methylphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(2-fluorophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-fluorophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-fluorophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(2-methoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-methoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-methoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(2-chlorophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-chlorophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-chlorophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(2-ethoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-ethoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-ethoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(2-bromophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-bromophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-bromophenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(2-phenoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-phenoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(4-hydroxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-[2-(3-trifluoromethylphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-(4-pyridinyl)-2-thiophenecarboxamide; 2-{[5-(4-pyridinyl)-2-thienyl]carbonyl}-1,2,3,4-tetrahydroisoquinoline;

```
5-(4-pyridinyl)-N-[2-(3-pyridinyl)ethyl]-2-thiophenecarboxamide;
5-(4-pyridinyl)-N-[2-(4-pyridinyl)ethyl]-2-thiophenecarboxamide;
N-(2-phenoxyethyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-[2-(1-piperidinyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-[2-(4-morpholinyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
1-phenyl-4-{[5-(4-pyridinyl)-2-thienyl]carbonyl}piperazine;
N-(1H-indazol-5-yl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
1-phenyl-8-{[5-(4-pyridinyl)-2-thienyl]carbonyl}-1,3,8-triazaspiro[4.5]decan-4-one;
ethyl 4-({[5-(4-pyridinyl)-2-thienyl]carbonyl}amino)-1-piperidinecarboxylate;
ethyl 1-{[5-(4-pyridinyl)-2-thienyl]carbonyl}-4-piperidinecarboxylate;
N-(1H-benzimidazol-2-ylmethyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
5-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]-2-thiophenecarboxamide;
N-[2-(3-hydroxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-[(1R)-1-phenylethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-[(1S)-1-phenylethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-[(1R)-1-(3-methoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-[(1S)-1-(3-methoxyphenyl)ethyl]-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-isopropyl-5-(4-pyridinyl)-2-thiophenecarboxamide;
1-methyl-4-{[5-(4-pyridinyl)-2-thienyl]carbonyl}piperazine;
N-phenyl-5-(4-pyridinyl)-2-thiophenecarboxamide:
N-(2-methoxyphenyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-(2-chlorophenyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-(4-methoxyphenyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-(4-chlorophenyl)-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-benzyl-5-(4-pyridinyl)-2-thiophenecarboxamide;
5-(2-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)-2-thiophenecarboxamide;
5-(2-amino-4-pyrimidinyl)-N-benzyl-2-thiophenecarboxamide;
5-(4-pyrimidinyl)-N-(3-methoxybenzyl)-2-thiophenecarboxamide;
5-(1H-indazol-5-yl)-N-(3-methoxybenzyl)-2-thiophenecarboxamide;
5-(6-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)-2-thiophenecarboxamide;
N-benzyl-4-bromo-5-(4-pyridinyl)-2-thiophenecarboxamide;
N-benzyl-4,5-di(4-pyridinyl)-2-thiophenecarboxamide;
N-(3-methoxybenzyl)-4,5-di(4-pyridinyl)-2-thiophenecarboxamide;
N-benzyl-5-[2-(methylamino)-4-pyrimidinyl]-2-thiophenecarboxamide;
N-benzyl-5-(1H-pyrazol-4-yl)-2-thiophenecarboxamide; and
N-(3-methoxybenzyl)-5-(1H-pyrazol-4-yl)-2-thiophenecarboxamide;
```

PR60715USW

or a salt, or solvate or physiologically functional derivative thereof.

10-11. (Cancelled)

12. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate ROCK-1 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as defined in <u>claim 1 any of claims 1-9</u>.

- 13. (Canceled)
- 14. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in <u>claim 1 any of claims 1-9</u> and one or more of pharmaceutically acceptable carriers, diluents and excipients.